Studie gegen therapieresistenten Typ-2-Diabetes (CAPTAIN-T2D) (CAPTAIN-T2D)
Clofutriben- und Placebo-Phase-2-Studie gegen therapieresistenten Typ-2-Diabetes (CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.
The trial consists of two parts.
Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.
During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Chandler, Arizona, Vereinigte Staaten, 85225
- Rekrutierung
- Arizona Clinical Trials - Pecos
-
Kontakt:
- Kamila Manager
- Telefonnummer: 480-470-4000
- E-Mail: kojeda@azclinicaltrials.com
-
Tucson, Arizona, Vereinigte Staaten, 85711
- Rekrutierung
- Arizona Clinical Trials - Broadway
-
Kontakt:
- Leanne Manager
- Telefonnummer: 480-470-4000
- E-Mail: lbuchenholz@azclinicaltrials.com
-
-
California
-
Fountain Valley, California, Vereinigte Staaten, 92708
- Rekrutierung
- Ark Clinical Research - Fountain Valley
-
Kontakt:
- Lizeth Manager
- Telefonnummer: 323-588-1990
- E-Mail: lsuncin@velocityclinical.com
-
Huntington Park, California, Vereinigte Staaten, 90255
- Rekrutierung
- Velocity Clinical Research, Huntington Park
-
Kontakt:
- Tim Manager
- Telefonnummer: 5135799911
- E-Mail: tpeterson@velocityclinical.com
-
La Mesa, California, Vereinigte Staaten, 91942
- Rekrutierung
- Velocity Clinical Research - Gardena
-
Kontakt:
- Tim Manager
- Telefonnummer: 513-673-4057
- E-Mail: tpeterson@velocityclinical.com
-
Long Beach, California, Vereinigte Staaten, 90815
- Rekrutierung
- Ark Clinical Research - Long Beach
-
Kontakt:
- Mike Manager
- Telefonnummer: 562-997-1000
- E-Mail: mdelgado@arkclinicalresearch.com
-
Los Angeles, California, Vereinigte Staaten, 90057
- Rekrutierung
- Velocity Clinical Research, Los Angeles
-
Kontakt:
- Tim Manager
- Telefonnummer: 5135799911
- E-Mail: tpeterson@velocityclinical.com
-
Los Angeles, California, Vereinigte Staaten, 90015
- Rekrutierung
- Los Angeles Institute for Metabolic Research
-
Kontakt:
- Lourdes Manager
- Telefonnummer: (213) 373-8380
- E-Mail: lgaribay@metabolic.la
-
Northridge, California, Vereinigte Staaten, 98433
- Rekrutierung
- Amicis Research Center- Nordhoff
-
Kontakt:
- Veronica Clinical Research Manager
- Telefonnummer: (818) 929-7774
- E-Mail: veronica.macias@amicisresearch.com
-
San Diego, California, Vereinigte Staaten, 92120
- Rekrutierung
- Alliance Clinical San Diego
-
Kontakt:
- Sandra Manager
- Telefonnummer: (858) 299-0009
- E-Mail: SMisic@allianceclinicalnetwork.com
-
-
Florida
-
Edgewater, Florida, Vereinigte Staaten, 32132
- Rekrutierung
- Velocity Clinical Research, New Smyrna Beach
-
Kontakt:
- Tim Manager
- Telefonnummer: 513-673-4057
- E-Mail: tpeterson@velocityclinical.com
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33312
- Rekrutierung
- The Center for Diabetes and Endocrine Care
-
Kontakt:
- Marie Study Coordinator
- Telefonnummer: ext 236 954-963-7191
- E-Mail: mmartin@diabetes-endocare.com
-
Miami, Florida, Vereinigte Staaten, 33173
- Rekrutierung
- Admed Research LLC
-
Kontakt:
- Indiana Manager
- Telefonnummer: 786-687-2882
- E-Mail: igonzalez@admedresearch.com
-
New Port Richey, Florida, Vereinigte Staaten, 34652
- Rekrutierung
- Suncoast Clinical Research, Inc
-
Kontakt:
- Cathy Manager
- Telefonnummer: 727-849-4131
- E-Mail: cbarnes@suncoastclinicalresearch.com
-
Port Charlotte, Florida, Vereinigte Staaten, 33952
- Rekrutierung
- Innovative Research Institute
-
Kontakt:
- Lauren Manager
- Telefonnummer: (+1) 2832276233
- E-Mail: l.ellis@medpace.com
-
Port Orange, Florida, Vereinigte Staaten, 32127
- Rekrutierung
- Progressive Medical Research
-
Kontakt:
- Nora Clinical Research Manager
- Telefonnummer: 3457 386-304-7070
- E-Mail: norab@progressivemedicalresearch.com
-
Winter Park, Florida, Vereinigte Staaten, 32789
- Rekrutierung
- Conquest Research
-
Kontakt:
- Malisa Manager
- Telefonnummer: 407-916-0060
- E-Mail: malisa.agard@conquestresearch.com
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30303
- Rekrutierung
- Emory University School of Medicine
-
Kontakt:
- Rohit Manager
- Telefonnummer: 404-778-1695
- E-Mail: rohit.parab@emory.edu
-
Columbus, Georgia, Vereinigte Staaten, 31904
- Rekrutierung
- IACT Health-Brookstone Centre Pkwy
-
Kontakt:
- kristina Manager
- Telefonnummer: 706.321.0495
- E-Mail: kristina.erb@centricityresearch.com
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83709
- Rekrutierung
- Paradigm Clinical Research - Boise, ID
-
Kontakt:
- Janaie Manager
- Telefonnummer: 208-801-7440
- E-Mail: jbounsana@paradigm-research.com
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60607
- Rekrutierung
- Chicago Clinical Research Institute
-
Kontakt:
- Manognya Clinical Research Manager
- Telefonnummer: 303 3127913241
- E-Mail: manognya@ccrii.us
-
-
Iowa
-
West Des Moines, Iowa, Vereinigte Staaten, 50226
- Rekrutierung
- Iowa Diabetes and Endocrinology Research Center
-
Kontakt:
- Crystal Manager
- Telefonnummer: 515-207-7486
- E-Mail: choffman@iderc.com
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten, 67226
- Rekrutierung
- Alliance for Multispecialty Research - Wichita East
-
Kontakt:
- Terry Manager
- Telefonnummer: 316-689-6635
- E-Mail: terry.klein@amr-clinical.com
-
-
Kentucky
-
Edgewood, Kentucky, Vereinigte Staaten, 41017
- Rekrutierung
- St. Elizabeth Healthcare
-
Kontakt:
- Amber Manager
- Telefonnummer: 859-655-1567
- E-Mail: amber.avery@stelizabeth.com
-
-
Louisiana
-
Lafayette, Louisiana, Vereinigte Staaten, 70508
- Rekrutierung
- Velocity Clinical Research, Lafayette
-
Kontakt:
- Tim Manager
- Telefonnummer: 513-673-4057
- E-Mail: tpeterson@velocityclinical.com
-
Metairie, Louisiana, Vereinigte Staaten, 70006
- Rekrutierung
- NOLA Care Clinical Research
-
Kontakt:
- Rosina Manager
- Telefonnummer: 504-427-6324
- E-Mail: rosinaducote@gmail.com
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Rekrutierung
- Tulane University School of Medicine
-
Kontakt:
- Neha Manager
- Telefonnummer: 5049889803
- E-Mail: nupadhyay@tulane.edu
-
-
Maryland
-
Rockville, Maryland, Vereinigte Staaten, 20854
- Rekrutierung
- Velocity Clinical Research, Rockville
-
Kontakt:
- Tim Manager
- Telefonnummer: 513-673-4057
- E-Mail: tpeterson@velocityclinical.com
-
-
Massachusetts
-
Springfield, Massachusetts, Vereinigte Staaten, 011030
- Rekrutierung
- Elixia SISU BHR - Springfield
-
Kontakt:
- Darlene Manager
- Telefonnummer: 5617970336
- E-Mail: darlene.djaba@empathxresearch.com
-
-
Michigan
-
Troy, Michigan, Vereinigte Staaten, 48085
- Rekrutierung
- Oakland Medical Research Center
-
Kontakt:
- Juliejo (Julie) Clinical Research Manager
- Telefonnummer: 248-687-7412
- E-Mail: juliejolafave@msn.com
-
-
Nebraska
-
Lincoln, Nebraska, Vereinigte Staaten, 68510
- Rekrutierung
- Velocity Clinical Research, Lincoln
-
Kontakt:
- Tim Manager
- Telefonnummer: 513-673-4057
- E-Mail: tpeterson@velocityclinical.com
-
Omaha, Nebraska, Vereinigte Staaten, 68134
- Rekrutierung
- Velocity Clinical Research, Omaha
-
Kontakt:
- Tim Manager
- Telefonnummer: 513-673-4057
- E-Mail: tpeterson@velocityclinical.com
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89148
- Rekrutierung
- Palm Research Center, Inc.
-
Kontakt:
- Raffaela Manager
- Telefonnummer: 702-736-5161
- E-Mail: raffaela@palmresearchcenter.com
-
Las Vegas, Nevada, Vereinigte Staaten, 89108
- Rekrutierung
- Alliance Clinical - Las Vegas
-
Kontakt:
- Stephanie Manager
- Telefonnummer: (702) 680-1500
- E-Mail: sruvalcaba@allianceclinicalnetwork.com
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12203
- Rekrutierung
- Albany Medical College
-
Kontakt:
- Mohammed Manager
- Telefonnummer: 518-264-4462
- E-Mail: ismailmoh@amc.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27514
- Rekrutierung
- University of North Carolina at Chapel Hill
-
Kontakt:
- Jessica Manager
- Telefonnummer: 984-974-3004
- E-Mail: jessica_caffey@med.unc.edu
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- Rekrutierung
- Physicians East
-
Kontakt:
- Kristen Manager
- Telefonnummer: 252-413-6392
- E-Mail: ktaylor@physicianseast.com
-
Morehead City, North Carolina, Vereinigte Staaten, 28557
- Rekrutierung
- Lucas Research Inc
-
Kontakt:
- Christina Manager
- Telefonnummer: 252-222-5700
- E-Mail: christina.tornes@centricityresearch.com
-
Wilmington, North Carolina, Vereinigte Staaten, 28401
- Rekrutierung
- PMG Research of Wilmington, LLC
-
Kontakt:
- Kevin Manager
- Telefonnummer: 910.815.6108
- E-Mail: cannon1099@me.com
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- Rekrutierung
- Velocity Clinical Research, Cincinnati, Mt. Auburn
-
Kontakt:
- Tim Manager
- Telefonnummer: 513-673-4057
- E-Mail: tpeterson@velocityclinical.com
-
Cincinnati, Ohio, Vereinigte Staaten, 45242
- Rekrutierung
- Velocity Clinical Research - Cincinnati, Blue Ash
-
Kontakt:
- Tim Manager
- Telefonnummer: 513-673-4057
- E-Mail: tpeterson@velocityclinical.com
-
Columbus, Ohio, Vereinigte Staaten, 43201
- Rekrutierung
- Endocrinology Associates, Inc
-
Kontakt:
- Edward Clinical Research Manager
- Telefonnummer: 614-453-9999
- E-Mail: ek@endocrinology-associates.com
-
Columbus, Ohio, Vereinigte Staaten, 43215
- Rekrutierung
- Remington Davis, Inc
-
Kontakt:
- Tsunami Clinical Research Manager
- Telefonnummer: 614-487-2560
- E-Mail: Tbrisco@remdavis.com
-
-
Oregon
-
Eugene, Oregon, Vereinigte Staaten, 97404
- Rekrutierung
- Willamette Valley Clinical Studies
-
Kontakt:
- Patricia Manager
- Telefonnummer: 541-461-0132
- E-Mail: drpatb@aol.com
-
-
Pennsylvania
-
West Chester, Pennsylvania, Vereinigte Staaten, 19380
- Rekrutierung
- Suburban Research Associates
-
Kontakt:
- Tom Manager
- Telefonnummer: 610-891-9024
- E-Mail: tfrancis@suburbanresearch.com
-
-
South Carolina
-
Anderson, South Carolina, Vereinigte Staaten, 29621
- Rekrutierung
- Velocity Clinical Research, Anderson
-
Kontakt:
- Tim Manager
- Telefonnummer: (864) 965-0190
- E-Mail: tpeterson@velocityclinical.com
-
Mt. Pleasant, South Carolina, Vereinigte Staaten, 29464
- Rekrutierung
- Accellacare Charleston
-
Kontakt:
- Dhruva Manager
- Telefonnummer: (843) 849-1880
- E-Mail: dhruva.patel@accellacare.com
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78759
- Rekrutierung
- Velocity Clinical Research, Austin
-
Kontakt:
- Tim Manager
- Telefonnummer: 513-673-4057
- E-Mail: tpeterson@velocityclinical.com
-
Dallas, Texas, Vereinigte Staaten, 75230
- Rekrutierung
- Velocity Clinical Research - Dallas
-
Kontakt:
- Tim Manager
- Telefonnummer: (972) 566-8631
- E-Mail: tpeterson@velocityclinical.com
-
Houston, Texas, Vereinigte Staaten, 77040
- Rekrutierung
- Juno Research, LLC
-
Kontakt:
- Lian manager
- Telefonnummer: 713-779-5494
- E-Mail: lian_ramos@junoresearch.us
-
Lampasas, Texas, Vereinigte Staaten, 76550
- Rekrutierung
- Radiance Clinical Research
-
Kontakt:
- Lauren Clinical Research Manager
- Telefonnummer: 512-556-4130
- E-Mail: lgarner@radianceclinical.com
-
Lewisville, Texas, Vereinigte Staaten, 75057
- Rekrutierung
- Alliance Clinical - Lewisville (Epic Clinical Research)
-
Kontakt:
- Jessica Manager
- Telefonnummer: (469) 361-8007
- E-Mail: jpowell@allianceclinicalnetwork.com
-
Mission, Texas, Vereinigte Staaten, 78572
- Rekrutierung
- Texas Valley Clinical Research - Mission, TX
-
Kontakt:
- Omar Manager
- Telefonnummer: 9568887400
- E-Mail: gonzalez.md@tvcrmission.com
-
Round Rock, Texas, Vereinigte Staaten, 78681
- Rekrutierung
- Texas Diabetes & Endocrinology, P.A. - Round Rock
-
Kontakt:
- Olivia Clinical Research Manager
- Telefonnummer: 512-334-3505
- E-Mail: knutty@tderesearch.com
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- Diabetes & Glandular Disease Clinic, P.A.
-
Kontakt:
- Myriam Manager
- Telefonnummer: 1532 210-614-8612
- E-Mail: myriam.turner@dgdclinic.com
-
San Antonio, Texas, Vereinigte Staaten, 78251
- Rekrutierung
- Texas Valley Clinical Research - San Antonio TX
-
Kontakt:
- Diana Manager
- Telefonnummer: 2105431990
- E-Mail: diana@tvcrtrials.com
-
Seabrook, Texas, Vereinigte Staaten, 77586
- Rekrutierung
- Elevate Clinical Research
-
Kontakt:
- Olga Clinical Research Manager
- Telefonnummer: 832-271-1598
- E-Mail: olga.konshina@elevateclinical.com
-
Weslaco, Texas, Vereinigte Staaten, 78596
- Rekrutierung
- Texas Valley Clinical Research, LLC
-
Kontakt:
- Czarina Manager
- Telefonnummer: 956-431-8090
- E-Mail: czarina@tvcrtrials.com
-
-
Utah
-
West Jordan, Utah, Vereinigte Staaten, 84088
- Rekrutierung
- Velocity Clinical Research, Salt Lake City
-
Kontakt:
- Tim Clinical Research Manager
- Telefonnummer: 5135799911
- E-Mail: tpeterson@velocityclinical.com
-
-
Virginia
-
Suffolk, Virginia, Vereinigte Staaten, 23435
- Rekrutierung
- Velocity Clinical Research, Suffolk
-
Kontakt:
- Tim Manager
- Telefonnummer: (757) 996-4200
- E-Mail: tpeterson@velocityclinical.com
-
Vienna, Virginia, Vereinigte Staaten, 22182
- Rekrutierung
- Conquest Research
-
Kontakt:
- Henry Manager
- Telefonnummer: 703-372-3268
- E-Mail: Henry.Tran@conquestresearch.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
From Screening 1
-
Age at least 18 years.
-
HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).
-
Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).
-
Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.
-
Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.
-
At least one of the following
- ≥3 stable and adequate ADMs;
- diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
- hypertension requiring ≥2 adequately dosed AHMs;
- adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
- adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
- evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
- or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.
-
At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.
At Screening 2
- HbA1c ≥7.5% at Screening 2. At Day 1
- No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.
Exclusion Criteria:
-
New-onset diabetes (onset <1 year in the past).
-
Unwillingness to maintain with current glucose-lowering regimen during the trial.
-
Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.
-
Unwillingness to comply with CGM or other trial procedures.
-
Investigator considers the patient will otherwise be unwilling or unable to complete the trial.
-
Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.
-
Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).
-
Any of the following in medical history:
- Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
- A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
- Hypersensitivity or severe reaction to dexamethasone;
- Pheochromocytoma, or suspicion thereof;
- Anorexia, or other eating disorder;
- Glucocorticoid resistance;
- Multiple sclerosis;
- Significant hepatic impairment (e.g., Child-Pugh Class B or C);
- Idiopathic thrombocytopenic purpura;
- Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
- Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
- Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
- Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
- Any of the following in medication history:
- Any of the excluded medications listed in Section 6.9;
- Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
- Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
- Pregnancy (including a positive urine test) or current breast feeding.
From Screening 2
• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:
- wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
- a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
- supraclavicular/dorsocervical fat accumulation;
- irounding of the face (especially compared with prior photos);
- skin changes (violaceous striae, skin thinning, or excessive bruising);
- proximal muscle weakness on exam; or
- history of deep vein thrombosis/pulmonary embolism.
- Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
- Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
- Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
- Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
- Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
- Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
- Known hypersensitivity to clofutriben or to any of the product
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Dose 1
clofutriben .2 mg oral tablet daily |
HSD-1 inhibitor
Andere Namen:
|
|
Experimental: Dose 2
clofutriben 2mg oral tablet daily |
HSD-1 inhibitor
Andere Namen:
|
|
Experimental: Dose 3
clofutriben 6mg oral tablet daily |
HSD-1 inhibitor
Andere Namen:
|
|
Experimental: Dose 4
clofutriben 12 mg oral tablet daily |
HSD-1 inhibitor
Andere Namen:
|
|
Placebo-Komparator: placebo
placebo control oral tablet daily |
Placebo |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Zeitfenster: 8-10 hours after the dexamethasone 1 mg dose.
|
To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose. |
8-10 hours after the dexamethasone 1 mg dose.
|
|
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Zeitfenster: 24 weeks.
|
To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Zeitfenster: 24 weeks
|
To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To evaluate the safety of clofutriben in participants with T2D and EC.
Zeitfenster: From enrollment until end of trial 9 month
|
Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose |
From enrollment until end of trial 9 month
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Neubildungen
- Stoffwechselerkrankungen
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Paraneoplastische Syndrome
- Nebennierenerkrankungen
- Nebennierenrindenüberfunktion
- Paraneoplastische endokrine Syndrome
- Ernährungs- und Stoffwechselerkrankungen
- Diabetes mellitus, Typ 2
- Cushing-Syndrom
- ACTH-Syndrom, ektopisch
- ASP3662
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- SPI-62-CL-2006
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .